Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer.

@inproceedings{Klein2013Abstract4T,
  title={Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer.},
  author={Christian Klein and Inja Waldhauer and Valeria G. Nicolini and Corrie S Dunn and Anne Freimoser-Grundschober and Sylvia Herter and Edwin J. W. Geven and Otto C Boerman and Tapan K. Nayak and Erwin van Puijenbroek and David Wittig and Samuel Moser and Oliver Ast and Peter Bruenker and Ralf J. Hosse and Sabine Lang and Sebastian Neumann and Hubert Kettenberger and Adelbert Grossmann and Ingo H. Gorr and Stefan Evers and Pavel Pi{\vs}a and Jennifer L Fretland and Victor Levitsky and Christian Gerdes and Marina Bacac and Ekkehard Moessner and Pablo Uma{\~n}a},
  year={2013}
}
IL-2 therapy can lead to durable responses in cancer patients, but is associated with significant toxicity. None of the described IL-2-based immunocytokines has progressed beyond Phase II trials due to various constraints in their design: 1) pM affinity for IL-2Rαβγ on immune cells and pulmonary vascular endothelium compromising tumor targeting due to the fusion of two wildtype IL-2 moieties to the antibody, together with FcγR binding on the same cells; 2) Rapid systemic clearance and short… CONTINUE READING